Publication | Closed Access

In vitro and in vivo studies on the development of the α-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinoma

EngineeringVivo StudiesRadiation TherapyMedicineRadionuclide TherapyIntraperitoneal UseTheranosticsGynecologyTumor TargetingMicroscopic Ovarian CarcinomaOncologyRadiation OncologyNuclear MedicineOvarian Cancer